A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Abroad (travel likely)RecruitingPHASE1

Conditions

Alzheimer's Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Clinical Trial Site, Montreal, Canada

  • Clinical Trial Site, Ottawa, Canada

  • Clinical Trial Site, Toronto, Canada

  • Clinical Trial Site, Toronto, Canada

  • Clinical Trial Site, 's-Hertogenbosch, Netherlands

  • Clinical Trial Site, Amsterdam, Netherlands

  • Clinical Trial Site, Barcelona, Spain

  • Clinical Trial Site, Madrid, Spain

  • Clinical Trial Site, Sant Cugat del Vallès, Spain

  • Clinical Trial Site, Glasgow, United Kingdom

  • Clinical Trial Site, London, United Kingdom

  • Clinical Trial Site, Sheffield, United Kingdom

  • Clinical Trial Site, Southampton, United Kingdom

Study leads
  • Medical Director

    Study Director

    Alnylam Pharmaceuticals